Insider transactions

Gregory M Weinhoff

CIK 1400975 · Chief Business Officer · last filed 2026-06-24

Gregory M Weinhoff is a Chief Business Officer who has filed 60 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
60
Lifetime Open-Market Net
-$6.49M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
CHESHIRE, X0 WA14 2DT
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Centessa Pharmaceuticals plc (CNTA) Delisted Chief Business Officer 0 $40.50 $0 -$5.64M 36 2026-06-24
AMICUS THERAPEUTICS, INC. (FOLD) Delisted Director 1,928,612 $14.49 $27.95M -$850.0K 3 2008-08-18

Recent Filings

60 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 Centessa Pharmaceuticals plc (CNTA) Delisted Disp (D) −65,925 $0 EDGAR
2026-03-26 — Notice (144) −23,998 -$675.5K EDGAR
2026-03-26 Centessa Pharmaceuticals plc (CNTA) Delisted Mixed — -$627.5K EDGAR
2026-03-13 — Notice (144) −73,196 -$1.99M EDGAR
2026-03-13 Centessa Pharmaceuticals plc (CNTA) Delisted Sell (S) −73,196 -$1.93M EDGAR
2026-02-03 Centessa Pharmaceuticals plc (CNTA) Delisted Mixed +16,842 -$347.9K EDGAR
2025-07-25 — Notice (144) −10,000 -$155.6K EDGAR
2025-07-25 Centessa Pharmaceuticals plc (CNTA) Delisted Mixed — -$117.1K EDGAR
2025-06-25 — Notice (144) −10,000 -$140.0K EDGAR
2025-06-25 Centessa Pharmaceuticals plc (CNTA) Delisted Mixed — -$100.1K EDGAR
Showing 1–10 of 60
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.